Page 61 - MEMORIA_SEHH-FEHH_2023

MEMORIA ANUAL 2023
SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
GESMD
FUNDACIÓN ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
• A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part
II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®)
Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With IPSS-R
Low- or Intermediate-risk Myelodysplastic Syndrome (MDS). Fase II/III. Hospital Univer-
sitario Central de Asturias. Finalizado el reclutamiento.
Activos en reclutamiento
• A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological
Malignancies With Isocitrate Dehydrogenase (IDH) Mutations. Fase I. Hospital Clínico
Universitario de Valencia, ICO L’Hospitalet-Hospital Duran i Reynals, Clínica Universidad
de Navarra, Hospital Universitario 12 de Octubre.
• A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Par-
ticipants With Acute Leukemia. Fase I. Hospital Universitario Fundación Jiménez Díaz,
Hospital Clínic de Barcelona, Clínica Universidad de Navarra, Hospital Universitari Vall
d’Hebron.
• A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malig-
nancies With IDH1 or IDH2 Mutations. Fase I. Hospital Clínic de Barcelona, Hospital
Universitario Fundación Jiménez Díaz, Hospital Universitari i Politècnic La Fe.
• A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Mi-
dostaurin in Combination With Induction and Consolidation Therapy Followed by
One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia
(AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mu-
tations Eligible for Intensive Chemotherapy (HOVON 156 AML/AMLSG 28-18). Fase
III. Hospital del Mar de Barcelona, ICO Badalona-Hospital Germans Trias i Pujol, ICO
L’Hospitalet-Hospital Duran i Reynals, Hospital Clínico Universitario de Valencia.
• A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of
Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation
Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute
Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2, With an IDH1
or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy. Fase III. ICO Ba-
dalona-Hospital Germans Trias i Pujol, Hospital del Mar de Barcelona, Hospital Clínico
Universitario de Valencia, ICO L’Hospitalet-Hospital Duran i Reynals.
61